Physician profile
Jill Ellen Wolf
NPI 1093792418
$9,108.66
in general payments reported to CMS, 2019-2025
29 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $931 · 2021: $1,155 · 2022: $695 · 2023: $4,102 · 2024: $585 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927 · Travel and Lodging: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.95 |
| Travel and Lodging | $2,472.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,480.67 | 2023 | Micra |
| Novo Nordisk INC | $2,108.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $866.68 | 2019-2025 | Farxiga |
| Abbott Laboratories | $690.00 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $395.72 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $204.92 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $158.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $141.09 | 2019-2023 | Belsomra |
| Abbvie INC. | $133.87 | 2022-2025 | |
| Exact Sciences Corporation | $114.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $94.80 | 2020-2025 | Otezla, Repatha, Repatha |
| Corcept Therapeutics | $92.66 | 2025 | Korlym |
| Eisai INC. | $75.14 | 2020-2022 | |
| Allergan, INC. | $71.87 | 2020 | |
| Avvisto Therapeutics, LLC | $49.86 | 2024-2025 | Cycloset |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.46 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $43.56 | 2025 | Recorlev, Gvoke Hypopen |
| Esperion Therapeutics, INC. | $41.30 | 2021-2024 | Nexletol |
| Pfizer INC. | $40.97 | 2021-2023 | |
| Dexcom, INC. | $38.13 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $35.94 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $31.81 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $26.42 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $24.49 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $22.85 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.68 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.82 | 2019 | |
| Lundbeck LLC | $18.82 | 2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.50 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.